Clinical Trials
Wednesday, February 26th, 2014
JAMA: 2/19/14 Importance Atrial fibrillation (AF) is the most common rhythm disorder seen in clinical practice. Antiarrhythmic drugs are effective for reduction of recurrence in patients with symptomatic paroxysmal AF. Radiofrequency ablation is an accepted therapy in patients for whom antiarrhythmic drugs have failed; however, its role as a first-line therapy needs further investigation. Objective To compare […]
Clinical Trials
Wednesday, February 26th, 2014
Clin Trials: January 24, 2014 Background Due to the cost and complexity of conducting a sequential multiple assignment randomized trial (SMART), it is desirable to pre-define a small number of personalized regimes to study. Purpose We proposed a simulation-based approach to studying personalized dosing strategies in contexts for which a therapeutic agent’s pharmacokinetic and pharmacodynamics properties are well […]
Clinical Trials
Wednesday, February 26th, 2014
CIRCEP: January 18, 2014 Background—In animal studies of radiofrequency ablation, lesion sizes plateau as the maximum lesion size is reached for an ablation. Lesion parameters are not available in clinical ablations, but preclinical work suggests that these correlate with impedance drop and electrogram attenuation. Characterization of the relationships between catheter contact force, ablation duration, and these […]
Clinical Trials
Wednesday, February 26th, 2014
CIRCOUTCOMES: January 14, 2014 Background—Recent proposals suggest that risk-stratified analyses of clinical trials be routinely performed to better enable tailoring of treatment decisions to individuals. Trial data can be stratified using externally developed risk models (eg, Framingham risk score), but such models are not always available. We sought to determine whether internally developed risk models, developed […]
Clinical Trials
Wednesday, February 26th, 2014
CIRCOUTCOMES: January 14, 2014 A composite end point is often used as the primary end point to assess the efficacy of a new treatment in randomized clinical trials. In cardiovascular trials, the often rare event of the relevant primary end point (individual or composite), such as cardiovascular death, myocardial infarction, or both, is combined with a […]
Therapies
Wednesday, February 26th, 2014
American Heart Association- Stroke: February 12, 2014 Because stroke is among the leading causes of death, disability, hospitalizations, and healthcare expenditures in the United States, there is interest in reporting outcomes for patients hospitalized with acute ischemic stroke. The American Heart Association/American Stroke Association, as part of its commitment to promote high-quality, evidence-based care for cardiovascular […]
Therapies
Wednesday, February 26th, 2014
American Stroke Association Meeting Late-Breaking Science Report Abstract: LB 2 (Hall E) February 12, 2014 Study Highlights: Amidst lingering debate, a review by an international collaboration of stroke experts shows timely use of clot busters improves stroke outcomes despite patient age or stroke severity. The clot-busting drug tPA can significantly reduce the risk of stroke […]
Therapies
Wednesday, February 26th, 2014
BMC: February 8, 2014 There is little evidence of service user preferences to guide the commissioning and improvement of services that support life after stroke. We report the first investigation of patients’ and family carers’ preferences for community services after stroke using a discrete choice experiment (DCE). Methods Two workshops with patients and family carers […]
Therapies
Wednesday, February 26th, 2014
STROKEAHA: February 4, 2014 Background and Purpose—Little is known about the effect of thrombolysis in patients with preexisting disability. Our aim was to evaluate the impact of different levels of prestroke disability on patients’ profile and outcome after intravenous thrombolysis. Methods—We analyzed the data of all stroke patients admitted between October 2003 and December 2011 that […]
Therapies
Wednesday, February 26th, 2014
Ahajournals: January 30, 2014 Background and Purpose—There are uncertainties surrounding the optimal management of patients with brain swelling after an ischemic stroke. Guidelines are needed on how to manage this major complication, how to provide the best comprehensive neurological and medical care, and how to best inform families facing complex decisions on surgical intervention in deteriorating […]
